Researchers sought to describe the clinical and sociodemographic characteristics of AYA patients with CLL. Patients who received CLL/SLL-directed therapies had a lower risk of Richter transformation. The prevalence of BTK C481 mutations might be higher in CLL patients with longer BTKi exposure. Venetoclax induces a distinct and prominent transcriptional response in patients with chronic lymphocytic leukemia.